Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
ZNecJEREJdPw86RN
